A Preclinical Physiological Assay to Test Modulation of Knee Joint Pain in the Spinal Cord: Effects of Oxycodone and Naproxen

Abstract

Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a test of the prediction that two clinically effective compounds, naproxen (an NSAID) and oxycodone (an opiate), are efficacious in reducing the response of spinal dorsal horn neurons to noxious knee joint rotation in the monosodium iodoacetate (MIA) sensitized rat. The overall objective for these experiments was to develop a high quality in vivo electrophysiology assay to confidently test novel compounds for efficacy against pain. Given the recent calls for improved preclinical experimental quality we also developed and implemented an Assay Capability Tool to determine the quality of our assay and ensure the quality of our results. Spinal dorsal horn neurons receiving input from the hind limb knee joint were recorded in anesthetized rats 14 days after they were sensitized with 1 mg of MIA. Intravenous administered oxycodone and naproxen were each tested separately for their effects on phasic, tonic, ongoing and afterdischarge action potential counts in response to innocuous and noxious knee joint rotation. Oxycodone reduced tonic spike counts more than the other measures, doing so by up to 85%. Tonic counts were therefore designated the primary endpoint when testing naproxen which reduced counts by up to 81%. Both reductions occurred at doses consistent with clinically effective doses for osteoarthritis. These results demonstrate that clinically effective doses of standard treatments for osteoarthritis reduce pain processing measured at the level of the spinal cord for two different mechanisms. The Assay Capability Tool helped to guide experimental design leading to a high quality and robust preclinical assay to use in discovering novel treatments for pain.

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

“…Sprague-Dawley rats have previously been used to assess the qEEG profile of subtype-selective GABA A PAMs (Nickolls et al, 2011) and, therefore, were considered a suitable species for these studies. Sample sizes were based on previous data and the assay capability tool (Miranda et al, 2014). Eight male Sprague-Dawley rats (~300 g, Charles River, Margate, Kent, UK) were anaesthetized using isoflurane (using 3% isoflurane anaesthesia in 100% O 2 and were maintained using 1.5-2.0% isoflurane in 100% O 2 as assessed by interdigital reflex), and impanted i.p.…”

The Antioxidant Machinery of Young and Senescent Human Umbilical Vein Endothelial Cells and Their Microvesicles

“…It should also be noted, however, that MVs have a highly specific antioxidant machinery: it is not simply a reduced version of that shown by endothelial cells but a selective reduction that suggests MVs carry a specific cargo. Certainly, specific mechanisms have been suggested for loading MVs with proteins [ 60 ], lipids [ 61 ], and RNA [ 62 ].…”

Increasing efficiency of preclinical research by group sequential designs

“…So far, however, they are virtually nonexistent in preclinical experiments. We performed text-mining of the complete PubMed Central Open Access subset (time frame: 2010–2014) and found only one article explicitly describing an original study evaluating a treatment in rats or mice using a sequential design [ 15 ] ( S1 Text ).…”